FDA Clarifies Stance on Compounded GLP-1 Receptor Agonists: Implications for Telehealth Weight Loss Programs

The U.S. Food and Drug Administration (FDA) has issued multiple warnings and guidance documents regarding the use of compounded versions of glucagon-like peptide-1 (GLP-1) receptor agonists, specifically semaglutide and tirzepatide. These actions underscore the agency's concerns about patient safety and the integrity of the drug supply chain, particularly as these medications gain widespread popularity for weight management and diabetes treatment. For telehealth platforms, medspas, and other healthcare businesses offering weight loss programs, understanding and adhering to the FDA's stance is critical for compliance and patient safety.

The FDA's Position on Compounded GLP-1 RAs

Since at least May 2023, the FDA has been vocal about the distinction between FDA-approved semaglutide (marketed as Ozempic and Wegovy) and tirzepatide (marketed as Mounjaro and Zepbound) and their compounded versions. The core of the FDA's concern revolves around several key points:

1. Lack of FDA Approval: Compounded drugs are not FDA-approved. This means they have not undergone the rigorous evaluation process for safety, effectiveness, and quality that approved drugs must pass. The FDA's approval process ensures that drugs meet specific standards for manufacturing, potency, purity, and labeling.
2. Drug Shortages and Compounding: Compounding of an FDA-approved drug is generally permissible under specific conditions outlined in Sections 503A and 503B of the Federal Food, Drug, and Cosmetic Act (FD&C Act). A primary condition is often the existence of a drug shortage for the approved product, as listed on the FDA's drug shortage database. When an approved drug is in shortage, pharmacists may compound a version of that drug. However, this permission is not blanket authority to compound under all circumstances.
3. Unauthorized Bulk Drug Substances: The FDA has specifically warned against the use of certain bulk drug substances for compounding semaglutide. For instance, the agency has noted that some compounding pharmacies use semaglutide salts (e.g., semaglutide sodium or semaglutide acetate) which are not the active ingredients in the FDA-approved Ozempic and Wegovy. The FDA has stated that it is not aware of any basis for compounding a drug using semaglutide salts that would meet the conditions for compounding under the FD&C Act. Furthermore, these salt forms have not been shown to be safe and effective.
4. Quality and Safety Concerns: The FDA has received adverse event reports related to compounded semaglutide products. These reports highlight potential risks associated with products that lack the same regulatory oversight as approved drugs, including issues with sterility, potency, and the presence of impurities.

Regulatory Framework for Compounding

The legal framework for drug compounding in the United States is primarily governed by Sections 503A and 503B of the FD&C Act. These sections differentiate between traditional compounding pharmacies (503A) and outsourcing facilities (503B):

• Section 503A (Traditional Compounding Pharmacies): These pharmacies compound drugs for individual patients based on a valid prescription. They are generally regulated by state boards of pharmacy and are subject to limitations on the quantities they can compound in anticipation of prescriptions.
• Section 503B (Outsourcing Facilities): These facilities can compound sterile drugs in bulk without patient-specific prescriptions. They are subject to more stringent federal oversight, including FDA registration and inspection, and must comply with current Good Manufacturing Practice (cGMP) requirements. However, even 503B facilities are limited in what they can compound, particularly concerning drugs that are essentially copies of commercially available FDA-approved products.

The FDA's warnings about compounded GLP-1 RAs emphasize that compounding these medications, especially when an FDA-approved version is available and not in shortage, or when using unapproved bulk drug substances, falls outside the legitimate scope of compounding under these sections.

Impact on Telehealth Weight Loss Programs and Medspas

The FDA's clear and repeated warnings have significant implications for healthcare businesses that offer weight loss services, particularly those leveraging telehealth models or operating as medspas:

1. Prescribing Practices and Due Diligence

• Source Verification: Providers must exercise extreme due diligence in verifying the source of any GLP-1 RA medication. If prescribing a compounded product, they must ensure the compounding pharmacy is legitimate, licensed, and adheres to all federal and state compounding laws. This includes confirming that the bulk drug substance used is appropriate and legally sourced.
• FDA Shortage List: Prescribing compounded versions of semaglutide or tirzepatide when the FDA-approved versions are not on the drug shortage list significantly increases regulatory risk. The FDA's position is that compounding is generally not appropriate when an approved drug is available.
• Salt Forms: Prescribing compounded semaglutide or tirzepatide using salt forms (e.g., semaglutide sodium, semaglutide acetate) that are not the active ingredients in the FDA-approved products is particularly risky, as the FDA has explicitly warned against these.

2. Patient Safety and Informed Consent

• Transparency: Telehealth providers and medspas must be transparent with patients about whether they are prescribing an FDA-approved drug or a compounded version. Patients must be fully informed of the differences, including the lack of FDA approval for compounded products and potential unknown risks.
• Adverse Event Reporting: Providers should be vigilant for adverse events and report them to the FDA, especially if they are associated with compounded products. This helps the FDA monitor the safety of the drug supply.

3. Marketing and Advertising Compliance

• Accurate Representation: Marketing materials for weight loss programs that include GLP-1 RAs must accurately represent the medications being offered. Misleading patients into believing they are receiving an FDA-approved drug when they are receiving a compounded product can lead to enforcement actions from the FDA, Federal Trade Commission (FTC), and state regulatory bodies.
• Avoid Unsubstantiated Claims: Claims about the efficacy or safety of compounded GLP-1 RAs should be avoided, as these products lack the clinical data supporting FDA-approved versions.

4. Pharmacy Partnerships

• Vetting Compounding Pharmacies: Healthcare businesses must thoroughly vet any compounding pharmacy they partner with. This includes checking their licensure, inspection history, and adherence to USP <797> (sterile compounding) and <795> (non-sterile compounding) standards. Ensure the pharmacy is not using unapproved bulk drug substances.
• 503B vs. 503A: Understand the differences between 503A and 503B pharmacies and ensure the chosen partner operates within the legal confines of their designation, especially if bulk compounding is involved.

Broader Regulatory Scrutiny

Beyond the FDA, state medical boards, pharmacy boards, and nursing boards often align with federal guidance on drug safety and compounding. Providers found to be prescribing or administering compounded GLP-1 RAs in violation of FDA guidance or state compounding laws could face disciplinary action, including license suspension or revocation. Furthermore, the Office of Inspector General (OIG) and other enforcement bodies may investigate practices involved in fraudulent schemes related to unapproved drugs.

Conclusion

The FDA's stance on compounded GLP-1 receptor agonists is a critical regulatory signal for the healthcare industry. For telehealth weight loss programs, medspas, and other practices, adherence to these guidelines is not merely a best practice but a legal imperative. Prioritizing FDA-approved medications, ensuring transparent patient communication, and rigorously vetting compounding pharmacy partners are essential steps to mitigate regulatory risk and ensure patient safety in this rapidly evolving therapeutic area.

References

• FDA Statement on Compounded Semaglutide: U.S. Food and Drug Administration. "Medications Containing Semaglutide Approved for Type 2 Diabetes or Weight Loss." Last updated May 2024. https://www.fda.gov/drugs/postmarket-drug-safety-information-patients-and-providers/medications-containing-semaglutide-approved-type-2-diabetes-or-weight-loss
• FDA Drug Shortages Database: U.S. Food and Drug Administration. "Drug Shortages." https://www.accessdata.fda.gov/scripts/drugshortages/
• FDA Compounding Information: U.S. Food and Drug Administration. "Compounding and the FDA: Questions and Answers." https://www.fda.gov/drugs/human-drug-compounding/compounding-and-fda-questions-and-answers
• FDA Statement on Compounded Tirzepatide: U.S. Food and Drug Administration. "FDA Warns Against Using Compounded Versions of Tirzepatide Due to Safety Concerns." Last updated December 2023. https://www.fda.gov/drugs/human-drug-compounding/fda-warns-against-using-compounded-versions-tirzepatide-due-safety-concerns